nicotine has been researched along with nimodipine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Baraldi, PG; Geppetti, P; Materazzi, S; Preti, D | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Arneric, SP; Donnelly-Roberts, DL; Sullivan, JP | 1 |
| Das, KP; Hong, JS; Hudson, PM; McMillian, MK; Suh, HW; Wilson, BC; Wu, GC | 1 |
| Damaj, MI; Martin, BR; Welch, SP | 1 |
| Hart, C; Kisro, NA; Ksir, C; Robinson, SL | 1 |
| Törnquist, K; Tuominen, RK; Vainio, PJ | 1 |
| Damaj, MI | 2 |
| Biala, G; Budzynska, B | 2 |
| Biala, G; Budzynska, B; Polak, P | 1 |
| Gullbrand, SE; Lawrence, JP; Ledet, EH; Lopes, L; Lotz, J; Mastropolo, R; Peterson, J | 1 |
1 review(s) available for nicotine and nimodipine
| Article | Year |
|---|---|
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Asthma; Humans; Ion Channel Gating; Neurons; Pain; Peripheral Nervous System Diseases; Pulmonary Disease, Chronic Obstructive; Transient Receptor Potential Channels | 2010 |
20 other study(ies) available for nicotine and nimodipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Cadmium; Calcium Channel Blockers; Calcium Channels; Diltiazem; Humans; Isradipine; Neuroblastoma; Neurons; Nicotine; Nifedipine; Nimodipine; omega-Agatoxin IVA; omega-Conotoxin GVIA; Peptides; Receptors, Nicotinic; Spider Venoms; Tumor Cells, Cultured; Verapamil | 1995 |
Long-term stimulation of nicotinic receptors is required to increase proenkephalin A mRNA levels and the delayed secretion of [Met5]-enkephalin in bovine adrenal medullary chromaffin cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenal Medulla; Animals; Base Sequence; Calcium-Calmodulin-Dependent Protein Kinases; Cattle; Cholinergic Antagonists; DNA Probes; Enkephalin, Methionine; Enkephalins; Enzyme Inhibitors; Gene Expression Regulation; Imidazoles; Isoquinolines; Molecular Sequence Data; Nicotine; Nicotinic Agonists; Nimodipine; Piperazines; Protein Precursors; RNA, Messenger; Transcription, Genetic | 1995 |
Characterization and modulation of acute tolerance to nicotine in mice.
Topics: Animals; Body Temperature; Dose-Response Relationship, Drug; Drug Tolerance; Male; Mice; Mice, Inbred ICR; Motor Activity; Nicotine; Nimodipine; Receptors, Nicotinic; Spinal Cord | 1996 |
Effects of the calcium channel blocker nimodipine on nicotine-induced locomotion in rats.
Topics: Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Male; Motor Activity; Nicotine; Nicotinic Agonists; Nimodipine; Rats; Rats, Sprague-Dawley | 1996 |
Cotinine and nicotine inhibit each other's calcium responses in bovine chromaffin cells.
Topics: Animals; Calcium; Cattle; Chromaffin Cells; Cotinine; Fluorescent Dyes; Fura-2; Hexamethonium; Nicotine; Nicotinic Agonists; Nimodipine; Tetrodotoxin; Thapsigargin | 2000 |
The involvement of spinal Ca(2+)/calmodulin-protein kinase II in nicotine-induced antinociception in mice.
Topics: Analgesics; Animals; Calcium; Calcium Channel Blockers; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Drug Interactions; Enzyme Inhibitors; Male; Mice; Nicotine; Nimodipine; Pain; Pain Measurement; Spinal Cord; Synaptosomes | 2000 |
Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Analgesics; Animals; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Drug Tolerance; Enzyme Activation; Enzyme Inhibitors; Injections, Spinal; Male; Mice; Nicotine; Nicotinic Agonists; Nimodipine; Pain Measurement; Reaction Time; Spinal Cord; Verapamil | 2005 |
Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists.
Topics: Animals; Behavior, Animal; Calcium Channel Blockers; Conditioning, Psychological; Extinction, Psychological; Flunarizine; Male; Morphine; Nicotine; Nimodipine; Rats; Rats, Wistar; Tobacco Use Disorder | 2006 |
Calcium-dependent mechanisms of the reinstatement of nicotine-conditioned place preference by drug priming in rats.
Topics: Animals; Benzoxazines; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Central Nervous System Depressants; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Ethanol; Extinction, Psychological; Flunarizine; Male; Morpholines; Naphthalenes; Nicotine; Nicotinic Agonists; Nimodipine; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Secondary Prevention; Tobacco Use Disorder | 2008 |
Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm.
Topics: Animals; Avoidance Learning; Calcium Channel Blockers; Drug Administration Schedule; Flunarizine; Male; Morphine; Motivation; Nicotine; Nimodipine; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Verapamil | 2012 |
Drug-induced changes to the vertebral endplate vasculature affect transport into the intervertebral disc in vivo.
Topics: Animals; Biological Transport; Diffusion; Intervertebral Disc; Magnetic Resonance Imaging; Microvessels; Nicotine; Nimodipine; Rabbits | 2014 |